表紙
市場調査レポート

Suda Ltdの製品パイプライン分析

Suda Ltd - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 321956
出版日 ページ情報 英文 30 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.51円で換算しております。
Back to Top
Suda Ltdの製品パイプライン分析 Suda Ltd - Product Pipeline Review - 2015
出版日: 2015年10月30日 ページ情報: 英文 30 Pages
概要

Suda Ltdはオーストラリアに本社を置くドラッグデリバリー企業で、口腔粘膜経路のドラッグデリバリー技術を医薬品開発用に提供しています。重症の小児マラリア治療のための舌下スプレーや、成人における急性片頭痛の治療に利用される口腔スプレーなどを製品として有しています。

当レポートでは、Suda Ltd における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

Suda Ltd の基本情報

  • Suda Ltd の概要
  • 主要情報
  • 企業情報

Suda Ltd :R&Dの概要

  • 主な治療範囲

Suda Ltd :パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

Suda Ltd :パイプライン製品の概況

  • 臨床段階にあるパイプライン製品
    • 第2相の製品/併用療法モダリティ
    • 第1相の製品/併用療法モダリティ
  • 開発段階が不明のパイプライン製品
    • 開発段階が不明の製品/併用療法モダリティ

Suda Ltd :薬剤プロファイル

  • sumatriptan succinate
  • sildenafil citrate
  • midazolam hydrochloride
  • ondansetron hydrochloride
  • SUD-004

Suda Ltd :パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Suda Ltd :最新のパイプライン情報

Suda Ltd :開発休止中のプロジェクト

Suda Ltd :開発が中止されたパイプライン製品

  • 開発が中止されたパイプライン製品のプロファイル
    • ondansetron hydrochloride
    • ropinirole hydrochloride

Suda Ltd :本社と子会社の所在地

  • 本社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07719CDB

Summary

Global Markets Direct's, 'Suda Ltd - Product Pipeline Review - 2015', provides an overview of the Suda Ltd's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Suda Ltd's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Suda Ltd including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Suda Ltd's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Suda Ltd's pipeline products

Reasons to buy

  • Evaluate Suda Ltd's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Suda Ltd in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Suda Ltd's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Suda Ltd and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Suda Ltd
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Suda Ltd and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Suda Ltd Snapshot
    • Suda Ltd Overview
    • Key Information
    • Key Facts
  • Suda Ltd - Research and Development Overview
    • Key Therapeutic Areas
  • Suda Ltd - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Suda Ltd - Pipeline Products Glance
    • Suda Ltd - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Suda Ltd - Unknown Stage Pipeline Products
      • Unknown Products/Combination Treatment Modalities
  • Suda Ltd - Drug Profiles
    • sumatriptan succinate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SUD-003
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SUD-004
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • midazolam hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ondansetron hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Suda Ltd - Pipeline Analysis
    • Suda Ltd - Pipeline Products by Target
    • Suda Ltd - Pipeline Products by Route of Administration
    • Suda Ltd - Pipeline Products by Molecule Type
    • Suda Ltd - Pipeline Products by Mechanism of Action
  • Suda Ltd - Recent Pipeline Updates
  • Suda Ltd - Dormant Projects
  • Suda Ltd - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • ondansetron hydrochloride
      • ropinirole hydrochloride
  • Suda Ltd - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Suda Ltd, Key Information
  • Suda Ltd, Key Facts
  • Suda Ltd - Pipeline by Indication, 2015
  • Suda Ltd - Pipeline by Stage of Development, 2015
  • Suda Ltd - Monotherapy Products in Pipeline, 2015
  • Suda Ltd - Phase II, 2015
  • Suda Ltd - Phase I, 2015
  • Suda Ltd - Unknown, 2015
  • Suda Ltd - Pipeline by Target, 2015
  • Suda Ltd - Pipeline by Route of Administration, 2015
  • Suda Ltd - Pipeline by Molecule Type, 2015
  • Suda Ltd - Pipeline Products by Mechanism of Action, 2015
  • Suda Ltd - Recent Pipeline Updates, 2015
  • Suda Ltd - Dormant Developmental Projects,2015
  • Suda Ltd - Discontinued Pipeline Products, 2015

List of Figures

  • Suda Ltd - Pipeline by Top 10 Indication, 2015
  • Suda Ltd - Pipeline by Stage of Development, 2015
  • Suda Ltd - Monotherapy Products in Pipeline, 2015
  • Suda Ltd - Pipeline by Top 10 Target, 2015
  • Suda Ltd - Pipeline by Top 10 Route of Administration, 2015
  • Suda Ltd - Pipeline by Top 10 Molecule Type, 2015
  • Suda Ltd - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top